Toulouse

Principal investigator:
Prof. Olivier Rascol

Toulouse III University
Laboratoire de Pharmacologie
Faculte de Medecine 37 Allees Jules Guesde
F-31073 Toulouse
rascol(at)cict.fr

Expertise of the participating organization:

The group is directly part of a number of complementary and multidisciplinary units which are all involved in the clinical management and research of patients with Parkinson's disease. The main activities and facilities are :

- The Clinical Research Centre (INSERM-Toulouse Hospital) with a team (doctors, nurses, pharmacists, technicians...) dedicated to clinical research with a special competence in pharmacology and drug development

- The Movement Disorders Clinic of the Department of Neurology, which is following-up several hundreds of patients with parkinsonism

- The Autonomic Nervous System Unit of the Department of Neurology which is following several hundreds of patients with dysautonomia

- The Neuroimaging Unit (INSERM U455) which offers MRI, SPECT and PET facilities


Recent publications relevant to the EMSA-SG:

Rascol O, Poewe W, Lees A, Aristin M, Salin L, Juhel N, et al. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study. Arch Neurol 2008; 65: 577-83. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18474731

Pavy-Le Traon A, Hughson RL, Thalamas C, Galitsky M, Fabre N, Rascol O, et al. Cerebral autoregulation is preserved in multiple system atrophy: A transcranial Doppler study. Mov Disord 2006; 21: 2122-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17029266

Rascol O. Defining a minimal clinically relevant difference for the unified Parkinson's rating scale: an important but still unmet need. Mov Disord 2006; 21: 1059-61. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16673409

Rascol O, Dubois B, Caldas AC, Senn S, Del Signore S, Lees A. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study. Mov Disord 2006; 21: 2110-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17013922

Rascol O, Brefel-Courbon C, Payoux P, Ferreira J. The management of patients with early Parkinson's disease. Adv Neurol 2003; 91: 203-11. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12442679

Rascol O, Goetz C, Koller W, Poewe W, Sampaio C. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002; 359: 1589-98. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12047983

Senard JM, Brefel-Courbon C, Rascol O, Montastruc JL. Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging 2001; 18: 495-505. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11482743